Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
47 participants
INTERVENTIONAL
2007-05-31
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Laboratory tests, including TG, total cholesterol, LDL-C, HDL-C, fibrinogen, D-Dimer, uric acid, vital signs and body weight will be evaluated at screening visit, 1 month, 3 months, 6 months visits after the initiation of treatment. Vital signs and body weight will be measured at every visits.
Patient self-evaluation of tolerance and physical improvement will be assessed by a Patient Questionnaire at each visit. Each patient will be carefully monitored for the development of any adverse events (AE).
The change of all lab tests and vital signs will be plotted and compared against time. Wilcoxon Signed-Rank test will be performed to compare the baseline and 6 months after the initiation of administration. Change from baseline for all lab and vital evaluations will be compared among three groups by Analysis of Variance (ANOVA) followed by LSD multiple comparison.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
nattokinase-mono formula (3500FU)
Nattokinase
2 capsules in the morning and before bed-time daily
B
Nattokinase compound-multiple formulae
Nattokinase
2 capsules in the morning and before bed-time daily
C
Placebo
Nattokinase
2 capsules in the morning and before bed-time daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nattokinase
2 capsules in the morning and before bed-time daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Dyslipidemic currently being untreated with lipid-lowering drugs. Dyslipidemia is defined as: Total cholesterol 200\~300 mg/dl; or Triglyceride 200\~500 mg/dl; or Low density lipoprotein-cholesterol 130\~200 mg/dl; or High density lipoprotein cholesterol \<40 mg/dl (male) and \<50 mg/dl (female).
3. Subjects who are, in the opinion of the Investigator, able to comply with the requirements of the study.
4. Subjects who have been adequately informed of the nature and risks of the study and who have given written informed consent prior to receiving investigational product.
Exclusion Criteria
2. Myocardial infarction within the preceding 12 weeks.
3. Recent major trauma (within 12 weeks).
4. Recent surgery requiring anesthesia including coronary artery bypass graft (within 12 weeks).
5. Recent hospitalization (within 12 weeks).
6. Acute infection requiring current antibiotic therapy.
7. Recent or abrupt change (within 1 month) in usual diet.
8. Unstable medical condition or life expectancy less than 6 months.
9. Known allergies to the component of study product.
10. Patients have acute disease, and in the opinion of investigators, are not suitable to participate in this study.
11. Total cholesterol \>300 mg/dl; or Triglyceride \>500 mg/dl; or Low density lipoprotein-cholesterol \>200 mg/dl.
12. Current use of warfarin.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GeneFerm Biotechnology Co., Ltd.
INDUSTRY
Chi Mei Medical Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chungchou Institute of Technology, Changhua, Taiwan
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nae-Cherng Yang, PhD
Role: STUDY_CHAIR
Chung Chou Institute of Technology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chi Mei Medical Hospital
Tainan City, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Yang NC, Chou CW, Chen CY, Hwang KL, Yang YC. Combined nattokinase with red yeast rice but not nattokinase alone has potent effects on blood lipids in human subjects with hyperlipidemia. Asia Pac J Clin Nutr. 2009;18(3):310-7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Geneferm-N01
Identifier Type: -
Identifier Source: org_study_id